Plasma polymerized nanoparticles effectively deliver dual siRNA and drug therapy in vivo

摘要: Multifunctional nanocarriers (MNCs) promise to improve therapeutic outcomes by combining multiple classes of molecules into a single nanostructure, enhancing active targeting agents and facilitating new combination therapies. However, nanocarrier platforms currently approved for clinical use can still only carry agent. The complexity escalating costs associated with the synthesis more complex MNCs have been major technological roadblocks in pathway translation. Here, we show that plasma polymerized nanoparticles (PPNs), synthesised reactive gas discharges, bind effectively deliver cargo facile cost-effective process compatible up scaled commercial production. Delivery siRNA against vascular endothelial growth factor (siVEGF) at extremely low concentrations (0.04 nM), significantly reduced VEGF expression hard-to-transfect cells when compared carrying higher doses (6.25 nM). PPNs siVEGF standard care Paclitaxel (PPN-Dual) (< 100 µg/kg) synergistically modulated microenvironment orthotopic breast tumors mice, tumor growth. We propose as nanomaterial delivery therapeutics, which be easily functionalised any laboratory setting without need additional wet-chemistry purification steps.